IceCure Medical Receives FDA Approval for ProSense™ in Brazil
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2025
0mins
IceCure Medical Ltd. saw a significant price drop of 12.69% as it crossed below its 5-day SMA amid positive market conditions, with the Nasdaq-100 up 1.79% and the S&P 500 up 0.80%.
The core catalyst for this movement is the recent FDA approval of IceCure's ProSense™ system for treating early-stage, low-risk breast cancer, which is expected to enhance commercial adoption in Brazil. Additionally, an independent study is enrolling 750 patients to evaluate ProSense™'s efficacy, and Dr. Toulsie Ramtohul will lead a 900-patient cryoablation study, further promoting the technology's recognition. IceCure's collaboration with KTR Medical aims to expand its market share in Brazil through enhanced clinical education and strategic partnerships.
Despite the stock's decline, the FDA approval and ongoing clinical studies indicate a strong potential for growth in the Brazilian oncology market, which could lead to increased revenue in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.610
Low
3.00
Averages
3.00
High
3.00
Current: 4.610
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IceCure Expands in Brazil's Oncology Market with ProSense™
- FDA Authorization Boost: IceCure's ProSense™ system received FDA approval for early-stage, low-risk breast cancer treatment, significantly increasing awareness and interest among Brazilian physicians and institutions, which is expected to enhance commercial adoption in Brazil.
- Clinical Research Progress: An independent study in Brazil is enrolling 750 breast cancer patients to evaluate the efficacy of ProSense™, demonstrating the technology's potential and effectiveness in clinical applications.
- International Collaboration: Dr. Toulsie Ramtohul from France will lead a 900-patient cryoablation study and share his expertise at a Brazilian oncology conference, further promoting ProSense™'s recognition and application in international markets.
- Market Promotion Strategy: IceCure is committed to promoting ProSense™ in Brazil through collaboration with KTR Medical and aims to expand market share by enhancing clinical education and forming strategic partnerships to improve patient quality of life.
See More
IceCure Medical Regains Nasdaq Compliance with Share Price Surge
- Share Price Recovery: IceCure Medical's stock price has remained above $1.00 for 10 consecutive trading days, leading to its compliance with Nasdaq's minimum bid requirement, with shares surging by 51.96%, which not only boosts investor confidence but may also attract more institutional interest.
- Compliance Notification: Nasdaq has officially closed the bid price deficiency matter for IceCure Medical, indicating significant progress in the company's stock price management, which will aid in the stability and sustainability of its presence in the capital markets.
- Reverse Split Strategy: IceCure Medical previously implemented a 1-for-30 reverse split to elevate its share price and regain Nasdaq compliance, demonstrating the company's proactive strategy in addressing market challenges aimed at enhancing shareholder value.
- Future Outlook: With compliance issues resolved, IceCure Medical is expected to showcase stronger performance in upcoming financial reports, further enhancing market confidence in its long-term growth potential.
See More
IceCure Medical Regains Nasdaq Compliance
- Compliance Notification: IceCure Medical received written notice from Nasdaq on June 18, 2026, confirming that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), marking a significant recovery in the company's market standing.
- Stock Performance: The company's ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive business days from June 4 to June 17, 2026, indicating stability and renewed investor confidence in IceCure's stock.
- Technological Focus: IceCure specializes in developing liquid-nitrogen-based cryoablation therapy systems, providing a safe and effective alternative to surgical tumor removal, primarily targeting breast, kidney, bone, and lung cancers, thereby strengthening its position in the medical technology sector.
- Market Implications: Regaining compliance not only enhances investor confidence but may also attract more institutional investors, creating favorable conditions for the company's future growth and technology adoption.
See More
Pulsenmore Soars 280% on Ouma Health Collaboration
- Strategic Partnership: Pulsenmore Ltd. has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the U.S., enabling the integration of its FDA-authorized home ultrasound platform, which is expected to significantly enhance customer satisfaction and strengthen market competitiveness.
- Stock Surge: Following the announcement of the partnership, Pulsenmore's stock soared by as much as 280%, closing up 93.26%, reflecting strong market confidence in its future growth potential.
- Technological Innovation: By introducing ultrasound monitoring into homes, Pulsenmore not only increases the frequency of contact between expectant mothers and their care teams but also potentially drives the adoption of virtual healthcare services, aligning with the industry's shift towards digital transformation.
- Market Outlook: This collaboration marks a significant positioning for Pulsenmore in the rapidly growing virtual healthcare market, likely attracting more investor attention and enhancing its standing within the industry.
See More
IceCure Medical Highlights Cryoablation Study in Top Surgical Journal
- Significant Clinical Outcomes: A study published by IceCure Medical in the International Journal of Surgery demonstrates that the ProSense® cryoablation technology shows clinical advantages over radiofrequency ablation (RFA) in treating early-stage breast cancer, particularly in tumor control rates and patient recovery, indicating its potential for widespread application.
- Strategic Focus on Japan: IceCure is preparing to present its findings at the 2026 Japanese Breast Cancer Society meeting and is collaborating with Terumo, one of Japan's largest medical device companies, to submit ProSense® for regulatory approval to Japan's Pharmaceuticals and Medical Devices Agency in the second half of 2026, further expanding its market reach.
- Distinct Technical Advantages: The research indicates that cryoablation provides local tumor control rates comparable to breast-conserving surgery for patients with small breast tumors, while offering shorter procedure times and improved cosmetic outcomes, thereby enhancing treatment options for patients.
- Enhanced Industry Recognition: The publication in the International Journal of Surgery, ranked third globally among surgical journals, not only boosts the recognition of ProSense® within the industry but may also accelerate global physician interest in cryoablation technology, promoting its adoption in breast cancer treatment.
See More
IceCure Medical Completes Private Placement Financing
- Financing Size: IceCure Medical has entered into securities purchase agreements with a single healthcare-focused institutional investor for the sale of 1,833,334 ordinary shares and corresponding Series D and E Warrants, with expected gross proceeds of approximately $5.5 million, reflecting investor confidence in its cryoablation technology.
- Warrant Terms: Both Series D and E Warrants have an exercise price of $3.00 per share and can be exercised immediately, which is expected to provide additional liquidity to the company to support its operations and R&D activities.
- Shareholder Approval: The company plans to reduce the exercise price of the March 2026 Series B and C Warrants from $16.50 to $3.00 upon obtaining shareholder approval, a move aimed at boosting investor confidence and facilitating future financing.
- Market Positioning: IceCure focuses on developing liquid nitrogen-based cryoablation systems primarily targeting breast, kidney, bone, and lung tumors, and with its minimally invasive technology, it is expected to enhance its competitive edge and expand its market share in the global healthcare sector.
See More
IceCure Expands in Brazil's Oncology Market with ProSense™
- FDA Authorization Boost: IceCure's ProSense™ system received FDA approval for early-stage, low-risk breast cancer treatment, significantly increasing awareness and interest among Brazilian physicians and institutions, which is expected to enhance commercial adoption in Brazil.
- Clinical Research Progress: An independent study in Brazil is enrolling 750 breast cancer patients to evaluate the efficacy of ProSense™, demonstrating the technology's potential and effectiveness in clinical applications.
- International Collaboration: Dr. Toulsie Ramtohul from France will lead a 900-patient cryoablation study and share his expertise at a Brazilian oncology conference, further promoting ProSense™'s recognition and application in international markets.
- Market Promotion Strategy: IceCure is committed to promoting ProSense™ in Brazil through collaboration with KTR Medical and aims to expand market share by enhancing clinical education and forming strategic partnerships to improve patient quality of life.
See More
IceCure Medical Regains Nasdaq Compliance with Share Price Surge
- Share Price Recovery: IceCure Medical's stock price has remained above $1.00 for 10 consecutive trading days, leading to its compliance with Nasdaq's minimum bid requirement, with shares surging by 51.96%, which not only boosts investor confidence but may also attract more institutional interest.
- Compliance Notification: Nasdaq has officially closed the bid price deficiency matter for IceCure Medical, indicating significant progress in the company's stock price management, which will aid in the stability and sustainability of its presence in the capital markets.
- Reverse Split Strategy: IceCure Medical previously implemented a 1-for-30 reverse split to elevate its share price and regain Nasdaq compliance, demonstrating the company's proactive strategy in addressing market challenges aimed at enhancing shareholder value.
- Future Outlook: With compliance issues resolved, IceCure Medical is expected to showcase stronger performance in upcoming financial reports, further enhancing market confidence in its long-term growth potential.
See More
IceCure Medical Regains Nasdaq Compliance
- Compliance Notification: IceCure Medical received written notice from Nasdaq on June 18, 2026, confirming that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), marking a significant recovery in the company's market standing.
- Stock Performance: The company's ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive business days from June 4 to June 17, 2026, indicating stability and renewed investor confidence in IceCure's stock.
- Technological Focus: IceCure specializes in developing liquid-nitrogen-based cryoablation therapy systems, providing a safe and effective alternative to surgical tumor removal, primarily targeting breast, kidney, bone, and lung cancers, thereby strengthening its position in the medical technology sector.
- Market Implications: Regaining compliance not only enhances investor confidence but may also attract more institutional investors, creating favorable conditions for the company's future growth and technology adoption.
See More
Pulsenmore Soars 280% on Ouma Health Collaboration
- Strategic Partnership: Pulsenmore Ltd. has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the U.S., enabling the integration of its FDA-authorized home ultrasound platform, which is expected to significantly enhance customer satisfaction and strengthen market competitiveness.
- Stock Surge: Following the announcement of the partnership, Pulsenmore's stock soared by as much as 280%, closing up 93.26%, reflecting strong market confidence in its future growth potential.
- Technological Innovation: By introducing ultrasound monitoring into homes, Pulsenmore not only increases the frequency of contact between expectant mothers and their care teams but also potentially drives the adoption of virtual healthcare services, aligning with the industry's shift towards digital transformation.
- Market Outlook: This collaboration marks a significant positioning for Pulsenmore in the rapidly growing virtual healthcare market, likely attracting more investor attention and enhancing its standing within the industry.
See More
IceCure Medical Highlights Cryoablation Study in Top Surgical Journal
- Significant Clinical Outcomes: A study published by IceCure Medical in the International Journal of Surgery demonstrates that the ProSense® cryoablation technology shows clinical advantages over radiofrequency ablation (RFA) in treating early-stage breast cancer, particularly in tumor control rates and patient recovery, indicating its potential for widespread application.
- Strategic Focus on Japan: IceCure is preparing to present its findings at the 2026 Japanese Breast Cancer Society meeting and is collaborating with Terumo, one of Japan's largest medical device companies, to submit ProSense® for regulatory approval to Japan's Pharmaceuticals and Medical Devices Agency in the second half of 2026, further expanding its market reach.
- Distinct Technical Advantages: The research indicates that cryoablation provides local tumor control rates comparable to breast-conserving surgery for patients with small breast tumors, while offering shorter procedure times and improved cosmetic outcomes, thereby enhancing treatment options for patients.
- Enhanced Industry Recognition: The publication in the International Journal of Surgery, ranked third globally among surgical journals, not only boosts the recognition of ProSense® within the industry but may also accelerate global physician interest in cryoablation technology, promoting its adoption in breast cancer treatment.
See More
IceCure Medical Completes Private Placement Financing
- Financing Size: IceCure Medical has entered into securities purchase agreements with a single healthcare-focused institutional investor for the sale of 1,833,334 ordinary shares and corresponding Series D and E Warrants, with expected gross proceeds of approximately $5.5 million, reflecting investor confidence in its cryoablation technology.
- Warrant Terms: Both Series D and E Warrants have an exercise price of $3.00 per share and can be exercised immediately, which is expected to provide additional liquidity to the company to support its operations and R&D activities.
- Shareholder Approval: The company plans to reduce the exercise price of the March 2026 Series B and C Warrants from $16.50 to $3.00 upon obtaining shareholder approval, a move aimed at boosting investor confidence and facilitating future financing.
- Market Positioning: IceCure focuses on developing liquid nitrogen-based cryoablation systems primarily targeting breast, kidney, bone, and lung tumors, and with its minimally invasive technology, it is expected to enhance its competitive edge and expand its market share in the global healthcare sector.
See More
